Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Search
Filing date Form Description View
8-K

Report of unscheduled material events or corporate event

 View HTML
0001104659-23-002083.pdf
0001104659-23-002083.rtf
0001104659-23-002083.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
3

Initial filing by director officer or owner of more than ten percent.

 View HTML
0001415889-23-000697.pdf
0001415889-23-000697.rtf
0001415889-23-000697.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-23-000700.pdf
0001415889-23-000700.rtf
0001415889-23-000700.xls
8-K

Report of unscheduled material events or corporate event

 View HTML
0001104659-23-001876.pdf
0001104659-23-001876.rtf
0001104659-23-001876.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
8-K

Report of unscheduled material events or corporate event

 View HTML
0001104659-22-130188.pdf
0001104659-22-130188.rtf
0001104659-22-130188.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-22-012194.pdf
0001415889-22-012194.rtf
0001415889-22-012194.xls
8-K

Report of unscheduled material events or corporate event

 View HTML
0001104659-22-124884.pdf
0001104659-22-124884.rtf
0001104659-22-124884.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
SC 13G/A

An amendment to the SC 13G filing

 View HTML
0000834237-22-010972.pdf
0000834237-22-010972.rtf
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-22-011112.pdf
0001415889-22-011112.rtf
0001415889-22-011112.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-22-011111.pdf
0001415889-22-011111.rtf
0001415889-22-011111.xls